Previous 10 | Next 10 |
Adial Pharmaceuticals press release ( NASDAQ: ADIL ): Q2 GAAP EPS of -$0.16 beats by $0.01 . As of June 30,2022, cash and cash equivalents were $9.2 million as compared to $6.1 million as of December 31, 2021, which the Company believes provides sufficient runway to ad...
Reported positive topline results for ONWARD™ Phase 3 trial of AD04 for the treatment of Alcohol Use Disorder Pursuing submission of ONWARD™ results with both European and U.S. regulatory agencies Actively exploring potential partnership opportunities for A...
Gainers: Direct Digital Holdings ( DRCT ) +81% . ToughBuilt Industries ( TBLT ) +54% . Stronghold Digital Mining ( SDIG ) +42% . Calithera Biosciences ( CALA ) +27% . CorMedix ( CRMD ) +23% . Allakos ( ALLK ) +22% ...
Gainers: Rhythm Pharmaceuticals ( RYTM ) +20% . Allakos ( ALLK ) +14% . Senti Biosciences ( SNTI ) +13% . Arcturus Therapeutics ( ARCT ) +7% . Verve Therapeutics ( VERV ) +5% . Losers: Vascular Biogenics ( VBLT ) -78%...
Vascular Biogenics ( VBLT ) -78% after late-stage trial for ovarian cancer treatment fails ; cut to Neutral at HC Wainwright after trial failure sinks stock 79%. Adial Pharmaceuticals ( ADIL ) -28% as AD04 fails to best placebo in very heavy drinkers in t...
Adial Pharmaceuticals' ( NASDAQ: ADIL ) AD04 could not show statistical significance in reducing heavy drinking days, compared to placebo, in very heavy drinkers in a phase 3 trial in patients with Alcohol Use Disorder (AUD). The company said that in the study, dubb...
AD04 achieved statistically significant mean reduction in heavy drinking days among pre-specified group of heavy drinkers, compared to placebo, with an approximately 79% reduction from baseline drinking AD04 demonstrated statistically significant difference in AUD severity, as c...
CHARLOTTESVILLE, Va., July 18, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and ...
CHARLOTTESVILLE, Va., June 28, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), today issued the following letter to its shareholders from the Company’s CEO, William Stilley. Dear Shareholders...
CHARLOTTESVILLE, Va., June 27, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and ...
News, Short Squeeze, Breakout and More Instantly...
Adial Pharmaceuticals Inc Company Name:
ADIL Stock Symbol:
NASDAQ Market:
Adial Pharmaceuticals Inc Website:
GLEN ALLEN, Va., June 20, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders,...
NEW YORK, NY / ACCESSWIRE / June 6, 2024 / Today the MicroCap Rodeo - Spring into Summer will take place in-person on Thursday, June 6th, 2024 and host the executive management teams of 25 microcap companies. The conference will be held live at Convene NYC, with company presentations from begin...